US Pharma MarketingThe accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.
Replimune rebounds to win FDA approval of melanoma drug
The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.
Source: BioPharma Dive